Screener
4D Molecular Therapeutics FDMT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accrued and other current liabilities | 22,866 | 26,874 |
| Deferred revenue | 360 | 360 |
| Operating lease liabilities, current portion | 5,486 | 5,592 |
| Total current liabilities | 43,404 | 43,985 |
| Deferred revenue, net of current portion | 2,125 | 745 |
| Derivative liability | 370 | 358 |
| Operating lease liabilities, long-term portion | 15,049 | 15,821 |
| Other liabilities | 121 | 138 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's total current liabilities?
- 4D Molecular Therapeutics (FDMT) reported total current liabilities of $43.4M in Q1 2026.
- How has 4D Molecular Therapeutics's total current liabilities changed year-over-year?
- 4D Molecular Therapeutics's total current liabilities increased by 61.4% year-over-year, from $26.9M to $43.4M.
- What is the long-term trend for 4D Molecular Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's total current liabilities has grown at a 21.3% compound annual growth rate (CAGR), from $16.74M to $43.99M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about 4D Molecular Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude